Date: Mar 10, 2014 Author: Lauren K. Ohnesorge Source: bizjournals (
click here to go to the source)
Lauren K. Ohnesorge
Staff Writer- Triangle Business Journal
Novan, which counts Cree (Nasdaq: CREE) founder Neal Hunter and GlaxoSmithKline (NYSE: GSK) veteran Bob Ingram among its investors, is fronted by CEO Nate Stasko.
The company is researching treatments based on nitric oxide - not to be confused with nitrous oxide, the laughing gas variety - with potential in wound care, acne and other areas of treatment, according to Stasko.
Last year, Novan earned a $7.8 million contract to develop its platform in burn care. Its big-name backers told me previously that the platform's flexibility makes the company attractive from an investing standpoint.
"(Novan) technology can impact so many different therapeutic areas," Hunter told me last year.
As for this round, Novan had 36 investors, according to a securities filing. The first sale happened on Feb. 24.
